公开(公告)号：US07858329B2

公开(公告)日：2010-12-28

申请号：US10529792

申请日：2003-09-30

申请人： Giuseppe Pier Pelicci ,  Saverio Minucci ,  Daniele Piccini ,  Marco Maccarana ,  Simona Ronzoni ,  Beatriz Liliana Areces ,  Mario Faretta

发明人： Giuseppe Pier Pelicci ,  Saverio Minucci ,  Daniele Piccini ,  Marco Maccarana ,  Simona Ronzoni ,  Beatriz Liliana Areces ,  Mario Faretta

IPC分类号： C07K16/30 ,  G01N33/574 ,  C12N5/06

CPC分类号： C12Q1/44 ,  C07K16/18

摘要： The invention relates to a method for determining whether a treatment of a disorder with an HDAC inhibitor is to be started/continued or not comprising determining the level of histone acetylation in the sample by use of an antibody capable of binding to acetylated histone, and classifying the disorder as to be treated with an HDAC inhibitor when the level of histone acetylation is significantly lower than that of a reference sample. The invention further relates to the diagnostic and prognostic use of specific antibodies and cell lines producing them.

摘要翻译： 本发明涉及一种用于确定是否开始/继续使用HDAC抑制剂治疗病症的方法，包括通过使用能够结合乙酰化组蛋白的抗体来确定样品中组蛋白乙酰化的水平，并分类 当组蛋白乙酰化水平显着低于参考样品的水平时，用HDAC抑制剂治疗的病症。 本发明还涉及特异性抗体和产生它们的细胞系的诊断和预测性应用。